Gilead Sciences Financials

GILD34 Stock  BRL 302.70  27.98  10.18%   
We strongly advise to harness Gilead Sciences fundamental analysis to see if markets are presently undervaluing or overvaluing the company. Simply put, you can make use of it to find out if Gilead Sciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to break down and interpolate thirty-one available reported financial drivers for Gilead Sciences, which can be compared to its competitors. The stock experiences a very speculative upward sentiment. Check odds of Gilead Sciences to be traded at R$378.38 in 90 days.
  
Understanding current and past Gilead Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gilead Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Gilead Sciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.

Gilead Sciences Stock Summary

Gilead Sciences competes with GP Investments, G2D Investments, Medical Properties, New Oriental, and MAHLE Metal. Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
InstrumentBrazil Stock View All
ExchangeSao Paulo Exchange
Business Address333 Lakeside Drive,
SectorHealthcare
IndustryDrug Manufacturers - Major
BenchmarkDow Jones Industrial
Websitewww.gilead.com
Phone650 574 3000
CurrencyBRL - Brazilian Real
You should never invest in Gilead Sciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Gilead Stock, because this is throwing your money away. Analyzing the key information contained in Gilead Sciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Gilead Sciences Key Financial Ratios

Gilead Sciences' financial ratios allow both analysts and investors to convert raw data from Gilead Sciences' financial statements into concise, actionable information that can be used to evaluate the performance of Gilead Sciences over time and compare it to other companies across industries.

Gilead Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gilead Sciences competition to find correlations between indicators driving Gilead Sciences's intrinsic value. More Info.
Gilead Sciences is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about  0.48  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Gilead Sciences is roughly  2.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Gilead Sciences Systematic Risk

Gilead Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gilead Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Gilead Sciences correlated with the market. If Beta is less than 0 Gilead Sciences generally moves in the opposite direction as compared to the market. If Gilead Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gilead Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gilead Sciences is generally in the same direction as the market. If Beta > 1 Gilead Sciences moves generally in the same direction as, but more than the movement of the benchmark.
JavaScript chart by amCharts 3.21.15NovDec2025Jan 13Jan 20Jan 27FebFeb 10275280285290295300 100200300400500600700 -0.0500.050.100.150.200.250.30 42K42.5K43K43.5K44K44.5K Show all
JavaScript chart by amCharts 3.21.15Gilead Sciences Volume Gilead Sciences Closing Prices Dow Jones Industrial Closing Prices - Benchmark Gilead Sciences Beta

Gilead Sciences February 16, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Gilead Sciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gilead Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gilead Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Gilead Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gilead Sciences's daily price indicators and compare them against related drivers.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity